XENO (Xeno Transplants) EPS (Basic): $-0.01 (TTM As of Mar. 2008)


What is Xeno Transplants EPS (Basic)?

Xeno Transplants XENO EPS (Basic) is $-0.01 as of Mar. 2008.

Xeno Transplants's basic earnings per share (Basic EPS) for the three months ended in Mar. 2008 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2008 was $-0.01.

Xeno Transplants's EPS (Diluted) for the three months ended in Mar. 2008 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2008 was $-0.01.

Xeno Transplants's EPS without NRI for the three months ended in Mar. 2008 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2008 was -0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Xeno Transplants  (OTCPK:XENO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Xeno Transplants EPS (Basic) Related Terms

Xeno Transplants EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Xeno Transplants's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeno Transplants EPS (Basic) Chart

Xeno Transplants Annual Data
Trend Jun05 Jun06 Jun07
EPS (Basic)
-0.01 -0.01 -0.00

Xeno Transplants Quarterly Data
Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.00 0.00

Xeno Transplants EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Xeno Transplants's Basic EPS for the fiscal year that ended in Jun. 2007 is calculated as

Basic EPS (A: Jun. 2007 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.128-0)/33.182
=-0.00

Xeno Transplants's Basic EPS for the quarter that ended in Mar. 2008 is calculated as

Basic EPS (Q: Mar. 2008 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.11-0)/40.364
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.01 mean?
Xeno Transplants (XENO) has a EPS (Basic) of $-0.01 as of Mar. 2008. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Xeno Transplants and its competitors.
Is Xeno Transplants' EPS (Basic) too high?
Xeno Transplants' current EPS (Basic) is $-0.01.
How does Xeno Transplants' EPS (Basic) compare to PRTX and GWSN?
Xeno Transplants' EPS (Basic) of $-0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Xeno Transplants and its competitors. Xeno Transplants's current EPS (Basic) is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeno Transplants stock overvalued right now?
Xeno Transplants (XENO) has a current EPS (Basic) of $-0.01. The current EPS (Basic) is $-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Xeno Transplants (XENO), the current EPS (Basic) is $-0.01 as of Mar. 2008. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xeno Transplants Business Description

Address 143 Gardner Road, Brookline, MA, USA, 02445
Xeno Transplants Corp is a bio-technology research and development company, which intends to develop therapeutic applications of organs and cells derived from genetically engineered pigs as a transplant alternative to limited human donor sources.